-
April 28, 2026
CLEVELAND — A federal judge in Ohio agreed to dismiss with prejudice hundreds of complaints pending in the Suboxone film multidistrict litigation based on the plaintiffs’ failure to comply with a case management order (CMO) after the makers of suboxone film, a prescription drug used to treat opioid use disorder, asked the court to order those plaintiffs to show cause or face dismissal.
-
April 28, 2026
CHICAGO — An Illinois federal judge granted a motion to dismiss filed by a medical device manufacturer after finding that a woman failed to explain how an allegedly defective tracheostomy tube led to the death of her adult son.
-
April 28, 2026
CLEVELAND — A federal judge in Ohio agreed to dismiss with prejudice hundreds of complaints pending in the Suboxone film multidistrict litigation based on the plaintiffs’ failure to comply with a case management order (CMO) after the makers of suboxone film, a prescription drug used to treat opioid use disorder, asked the court to order those plaintiffs to show cause or face dismissal.
-
April 27, 2026
NEW ORLEANS — The Louisiana federal judge overseeing the multidistrict litigation involving cases alleging that a chemotherapy drug caused eye injuries on April 24 denied a motion filed by the manufacturer to exclude an expert retained by the plaintiffs from testifying and agreed to limit what the manufacturer’s expert can opine about in relation to the label on the drug.
-
April 27, 2026
GREENBELT, Md.— A pharmaceutical company insured filed a notice appealing a Maryland federal court’s grant of a directors and officers liability insurer’s motion to dismiss its breach of contract and bad faith lawsuit seeking a declaration as to coverage for an underlying antitrust action arising from its acquisition of the rights to distribute a prescription medication used to treat mobility issues in people with advanced Parkinson's disease.
-
April 27, 2026
BOSTON — In a challenge by physicians’ professional groups and others to the Centers for Disease Control and Prevention’s changes to vaccine recommendations and the reconstitution of the Advisory Committee on Immunization Practices (ACIP), the federal government moved for a stay of the proceedings pending the resolution of any appeal it might seek of a Massachusetts federal court’s grant of preliminary relief that stayed a January U.S. Department of Health and Human Services memorandum announcing the reduction of the recommended childhood vaccinations from 17 to 11 and the appointment of 13 new ACIP members.
-
April 27, 2026
WASHINGTON, D.C. — The manufacturers of Dupixent, a prescription medication used for the treatment of asthma and inflammatory skin conditions, and individuals in cases across the country that allege that the drug causes cutaneous T-cell lymphoma (CTCL), a rare type of cancer that affects white blood cells called T cells or T lymphocytes, will be able to present oral arguments on May 28 before the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) on which federal court the cases should be centralized.
-
April 24, 2026
SAN FRANCISCO — A California federal judge found that Eli Lilly and Co. established standing in its amended complaint alleging unfair competition and false advertising claims against a telehealth company that sells a compounded version of tirzepatide, a U.S. Food and Drug Administration-approved drug for diabetes and weight loss, and largely denied the company’s motion to dismiss.
-
April 23, 2026
PHILADELPHIA — Counsel for a man with a case pending in a Zantac mass tort litigation centralized in the Philadelphia County Court of Common Pleas appealed a judge’s refusal to recuse himself from all Zantac cases over claims that the judge’s wife’s involvement with Zantac litigation created a conflict of interest.
-
April 22, 2026
RICHMOND, Va. — A district court did not abuse its discretion in refusing to amend a scheduling order to extend an expert disclosure deadline for a man who alleges that he was injured by the defective stapler, the Fourth Circuit U.S. Court of Appeals held, affirming summary judgment for the manufacturer.
-
April 16, 2026
New developments in the following mass tort drug and device cases are marked in boldface type.
-
April 16, 2026
NEW ORLEANS — The Fifth Circuit U.S. Court of Appeals will consider through an interlocutory appeal whether the Louisiana federal judge overseeing a multidistrict litigation involving a chemotherapy drug that allegedly caused eye injuries erred in denying summary judgment to a manufacturer and rejecting its argument that the claims against it are preempted by federal law.
-
April 16, 2026
NEW YORK — McKinsey & Co. Inc. has agreed to contribute $125 million to a trust to settle any claims that the consulting company helped Purdue Pharma LP contribute to the opioid epidemic through its work devising and implementing opioid sales and marketing strategies, according to a notice filed in Purdue’s bankruptcy case pending in the U.S. Bankruptcy Court for the Southern District of New York.
-
April 15, 2026
HOUSTON — The family of a woman who died after taking compounded semaglutide from a Texas-based compounding pharmacy seeks to represent a nationwide class of consumers who purchased medications or health care providers who sourced their medications from the pharmacy, which they allege “disregard[ed] regulatory requirements and patient safety,” according to a complaint filed in a Texas state court.
-
April 15, 2026
SAN FRANCISCO — A California federal judge will allow a woman one more chance to amend her putative class complaint alleging that companies violated various California consumer protection laws by manufacturing and selling products containing benzene.
-
April 15, 2026
WASHINGTON, D.C. — The U.S. Supreme Court should let stand a Seventh Circuit U.S. Court of Appeals decision that affirmed a final judgment of $193 million for a qui tam relator who sued Eli Lilly & Co. for reporting falsely deflated drug prices to the government in order to profit off of drug rebate programs because the two questions presented to the high court by the drug manufacturer “are uniquely poor candidates for this Court’s review,” the relator contends in an April 14 opposition brief.
-
April 15, 2026
BOISE, Idaho — Albertsons Companies Inc. announced in an April 14 press release that “it has reached a $774 million settlement framework to resolve substantially all of the opioid-related claims brought against the Company by state, local and tribal government entities nationally.”
-
April 14, 2026
ST. LOUIS — Missouri, Idaho and Kansas, which are challenging the U.S. Food and Drug Administration’s approval of mifepristone, one of two drugs used to induce early termination of pregnancy, point to a recent decision by a Louisiana federal court that granted the FDA’s motion to stay all proceedings in that case but also found that the state had standing.
-
April 13, 2026
WICHITA FALLS, Texas — The drug manufacturers of mifepristone, one of two drugs used to induce early termination of pregnancy, moved separately in a Texas federal court to dismiss a case brought by Florida and Texas that challenges the U.S. Food and Drug Administration’s approval in 2000 of mifepristone and the agency’s subsequent approvals, including allowing the drug to be mailed.
-
April 10, 2026
NEW HAVEN, Conn. — A woman who alleges that a defective pacemaker had to be removed and caused injuries argues in a motion to remand that “[c]omplete diversity between the parties does not exist” and that the case was wrongly removed to a Connecticut federal court.
-
April 09, 2026
LAFAYETTE, La. — Louisiana and a woman, who are challenging the validity of the U.S. Food and Drug Administration’s 2023 decision to remove the in-person dispensing requirement for mifepristone, on April 8 appealed to the Fifth Circuit U.S. Court of Appeals a decision by a federal judge that denied their motion for a preliminary injunction and granted the FDA’s motion to stay the case while the agency conducts a review of its previous rulings.
-
April 09, 2026
WASHINGTON, D.C. — A man diagnosed with Stage IV lung cancer who requires ongoing treatment from medical providers in California was unable to convince the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) that his case should not be transferred to the multidistrict litigation involving the recall of approximately 10.8 million continuous positive air pressure (CPAP) sleep apnea devices pending in a Pennsylvania federal court.
-
April 08, 2026
JACKSON, Miss. — Mississippi told a federal court in the state that a recent decision by the Maryland Supreme Court that the dispensing of opioids by pharmacy benefit managers (PBMs), mail order pharmacies and retail pharmacies does not constitute an actionable public nuisance “applies vastly different state law” and does not support PBMs’ motion to dismiss claims pending against them in a Mississippi federal court.
-
April 08, 2026
DETROIT — A Michigan federal judge refused to remand to state court a case filed by the attorney general for Michigan alleging that two of the nation’s largest pharmacy benefit managers (PBMs) violated the state’s public nuisance laws by contributing to the oversupply of opioids.
-
April 08, 2026
NEW YORK — A New York federal judge adopted the recommendations from a magistrate judge and agreed to partially grant a motion to dismiss filed by a cochlear implant manufacturer after finding that many claims are preempted by federal law.